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outcome. Additionally, education and sewage disposal ser-
vice variables that were collected through household-level
interviews or retrieved from IBGE census tract data were
associated with HAV infection in all sites.
Conclusion: The study sites were classiﬁed as areas with
low endemicity area for hepatitis A infection. This multilevel
model allowed for quantiﬁcation of contextual predictors of
hepatitis A infection in urban areas.
doi:10.1016/j.ijid.2010.02.2010
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Background: In 1989, the Brazilian government ﬁrst
implemented immunization against hepatitis B for infants
and children in the western Amazon region and gradually
expanded this to other regions. Vaccination of risk groups
for the whole country started in 1992, and new groups have
been successively added to the original list. Since 1998,
the HBV vaccine has been incorporated into the immuniza-
tion schedule for infants as a national policy and, in 2001,
this was broadened to include children and adolescents.
Ppopulation-based survey was conducted in Brazil to esti-
mate the prevalence of and risk factors for HBV infection
from South and Southeast region of Brazil.
Methods: Random multistage cluster sampling was used
to select individuals aged 13-69 years. Outcomes indicat-
ing HBV infection were anti-HBc and HBsAg. HBsAg-positive
samples were tested for HBV-DNA and genotyped. Univariate
and multivariate analyses were performed.
Results: Overall, 10.496 individuals were included; the
prevalence of anti-HBc was: South 1,58% for 10—19 and 11,3
for 20—69 years old; Southeast 0,61% for 10—19 and 7,9 for
20—69 years old. HBsAg positivity was less than 0,5% in all
areas. Genotypes 3A, 1b,1a and 2b were identiﬁed. Age were
associate with HBV infection in all region and male were
independently associated with HBV infection in Southeast.
Conclusion: Our survey classiﬁed the South and Southeast
region of Brazil as low HBV endemicity areas. Our ﬁndings
that age is risk factors for HBV reinforce the need for exten-
sive HBV vaccine coverage among adolescents to prevent
viral infection. All individuals belonging to the risk groups
identiﬁed by our survey should be considered candidates for
HBV vaccine and educational measures. Therefore, vaccina-
tion upon request for individuals without speciﬁc risk should
be considered, in accordance with the current CDC recom-
mendations. This survey shows the importance of generating
r
dts e235
opulation-based information to facilitate comprehensive
accination and of developing educational strategies that
ddress regional differences.
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Background: Hepatitis A is an acute, usually self-limiting
isease of the liver, caused by hepatitis A virus. Patients
ith chronic liver disease are at increased risk of severe
omplications, related to hepatitis A, which, in some
ircumstances, may even lead to death. Therefore, it
s postulated that HAV susceptible individuals (anti-HAV
eronegative subjects) should be vaccinated against HAV to
revent or diminish morbidity and mortality of the disease.
im: Evaluation of the prevalence of anti-HAV antibodies
mong patients in different age groups with chronic hepati-
is C.
Methods: 133 patients (the mean age: 38.3 yrs) with CHC
ere divided into two groups, according to age (Table 1).
he control group consisted of 150 healthy young medical
tudents (the mean age: 25.3 yrs). The presence of anti-
AV and addition of HBV infection viral markers: anti HBc
nd HBsAg in blood sera of the patients and of the control
roup were assessed, using the standard EIA method (Cobas
oche).
Results: The prevalence of anti HAV antibodies and HBV
nfectionmarkers among the evaluated groups are presented
n Table 1.
roup Age
years
Pt n anti HAV Anti-HBc HBsAg
n % n % n %
HC 18—30 33 5 15.5 6 18.8 0 0
31—73 100 47 47.0 27 27.0 2 2
ontrol
24—26
150 15 10.0 8 5.3 2 1.33
In the study groups, age-dependent, differentiated
revalence of anti-HAV and anti-HBc was observed among
ounger (< 31 years) and older (> 30 years) patients with CHC
15.5% vs. 47.0%; p = 0.05 and 18.8% vs. 27%, p = 0.05, respec-
ively), which was higher than in healthy controls (10.0% and
.3%, respectively).
Conclusion: Patients below 31 with CHC present signif-
cantly lower anti-HAV and anti-HBc prevalence than older
nes, what creates a substantial risk for fulminant liver fail-
re and even death in case of HAV or HBV infection. Thus
accination programmes against HAV and HBV are strongly
ecommended in these groups of patients.
oi:10.1016/j.ijid.2010.02.2012
